Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,987,904 | 4,726,513 | 5,934,540 | 6,877,260 | 6,541,940 |
| Marketable Securities | 486,358 | 504,456 | 557,600 | 659,920 | 1,535,110 |
| Receivables | 3,922,593 | 3,934,606 | 4,248,140 | 4,401,940 | 4,370,200 |
| Inventories | 2,254,984 | 2,276,558 | 2,387,420 | 2,487,390 | 2,663,180 |
| Other current assets | 485,971 | 624,007 | 704,960 | 566,850 | 555,830 |
| TOTAL | $12,137,810 | $12,066,140 | $13,832,660 | $14,993,360 | $15,666,260 |
| Non-Current Assets | |||||
| PPE Net | 4,244,361 | 4,314,241 | N/A | N/A | N/A |
| Investments And Advances | 2,333,630 | 2,556,481 | 2,565,890 | 2,459,110 | 2,355,870 |
| Intangibles | 14,156,275 | 14,840,393 | 0 | 0 | 0 |
| Other Non-Current Assets | 1,681,324 | 1,653,725 | 17,908,700 | 18,746,930 | 20,728,630 |
| TOTAL | $22,415,590 | $23,364,840 | $20,474,590 | $21,206,040 | $23,084,500 |
| Total Assets | $34,553,400 | $35,430,970 | $39,095,350 | $40,949,670 | $43,889,340 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 819,861 | 819,787 | 909,680 | 1,599,760 | N/A |
| Accounts payable and accrued liabilities | 1,292,796 | 1,417,764 | 1,554,110 | 1,482,690 | 1,490,140 |
| Other current liabilities | 5,417,633 | 5,589,620 | 6,415,560 | 3,643,410 | 3,633,030 |
| TOTAL | $8,085,036 | $8,289,782 | $9,253,090 | $7,373,690 | $7,479,950 |
| Non-Current Liabilities | |||||
| Long Term Debt | 5,158,193 | 5,192,109 | 5,727,680 | 6,433,530 | 6,861,700 |
| Other Non-Current Liabilities | 2,184,768 | 2,324,962 | 2,617,561 | 2,328,970 | 2,695,010 |
| TOTAL | $8,573,379 | $8,841,904 | $9,766,041 | $10,934,730 | $12,112,430 |
| Total Liabilities | $16,658,420 | $17,131,680 | $19,019,150 | $18,308,440 | $19,592,400 |
| Shareholders' Equity | |||||
| Common Shares | 528,949 | 526,538 | 582,800 | 560,910 | 611,120 |
| Retained earnings | 13,063,860 | 12,808,320 | 14,572,070 | 16,059,750 | 18,039,950 |
| Other shareholders' equity | 4,098,027 | 4,792,827 | 4,545,200 | 5,681,780 | 5,300,490 |
| TOTAL | $17,894,970 | $18,299,290 | $20,076,200 | $22,641,230 | $24,296,940 |
| Total Liabilities And Equity | $34,553,390 | $35,430,970 | $39,095,350 | $40,949,670 | $43,889,340 |